Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRBJ1-1 (T cell receptor beta joining 1-1) is a gene segment located within the TCR beta locus. It encodes one of the joining (J) regions that are recombined during T cell development to generate the variable domain of the beta chain of the T cell receptor (TCRβ)[3][5]. This recombination, involving variable (V), diversity (D), and joining (J) gene segments, allows an individual’s immune system to generate a diverse repertoire of TCRs for antigen recognition[2][5]. The T cell receptor itself is a membrane-bound protein complex on T lymphocytes, crucial for the specific recognition of antigens presented by major histocompatibility complex (MHC) molecules[2][4][5]. The diversity of TCRs, created in part by segments such as TRBJ1-1, is vital for effective immune surveillance and response[5]. However, TRBJ1-1 is not itself a protein, receptor, or protypical therapeutic target or receptor, but one of several building blocks for the TCR complex.
Not applicable; TRBJ1-1 is not directly druggable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor beta joining 1-1 (TRBJ1-1).